Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Andrew R. Robbins M.B.A. | President, CEO & Director | 1.06M | -- | 1976 |
| Dr. John Edward Robinson Ph.D. | Chief Scientific Officer | 749.89k | -- | 1975 |
| Dr. Jessica Sachs M.D. | Chief Medical Officer | 773.92k | -- | 1975 |
| Mr. John L. Green C.A., CPA | CFO & Principal Accounting Officer | 763.99k | -- | 1980 |
| Mr. Brad Barnett | Chief Technology Officer | -- | -- | -- |
| Ms. Christi Waarich | Senior Director of Investor Relations | -- | -- | -- |
| Mr. Evan D. Kearns J.D. | Chief Legal Officer & Corporate Secretary | -- | -- | 1980 |
| Ms. Erin Schellhammer | Chief People Officer | -- | -- | -- |
| Mr. Dana R. Martin Pharm.D. | Senior VP of Medical Affairs & Chief Patient Officer | -- | -- | -- |
| Brad Fell | Senior Vice President of Chemistry | -- | -- | -- |
Cogent Biosciences, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 205
Description
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
Corporate Governance
Upcoming Events
May 5, 2025 at 12:30 PM UTC - May 9, 2025 at 12:30 PM UTC
Cogent Biosciences, Inc. Earnings Date